1. Quality of life in patients with diffuse large B-cell lymphoma treated with dose-dense chemotherapy is only affected temporarily.
- Author
-
Tholstrup, Dorte, brown, Peter De nully, Jurlander, Jesper, Bekker jeppesen, Palle, and Groenvold, Mogens
- Subjects
- *
LYMPHOMAS , *QUALITY of life , *B cell lymphoma , *DRUG therapy , *SYMPTOMS , *DRUG side effects , *PATIENTS - Abstract
(R)-CHOP-14 has substantially improved outcome in DLBCL, but may have increased morbidity and reduced quality of life (QoL). Our aim was to evaluate QoL during (R)-CHOP-14-based chemotherapy. Twenty-six patients participated (small single-center study). EORTC QLQ-C30 was completed pre-treatment, mid-treatment, 14 days post-treatment, and 3 months post-treatment. Scores were compared to a reference population, and analyzed separately. Pre-treatment, global health status ( p == 0.004), physical functioning ( p == 0.036), role functioning ( p == 0.017), and emotional functioning ( p == 0.040) were reduced, and fatigue ( p == 0.009) and appetite loss ( p == 0.007) increased compared to the reference population. During treatment, physical functioning and role functioning decreased significantly, whereas emotional functioning, fatigue, and diarrhea increased. Three months post-treatment, scores were generally equivalent to those of the reference population, and lower for nausea/vomiting ( p < 0.001) and constipation ( p < 0.001). Disease-related symptoms were frequent in high-risk DLBCL. Treatment-related symptoms were normalized 3 months post-treatment. In conclusion, QoL is only temporarily affected during (R)-CHOP-14-based chemotherapy, and the treatment regimen is therefore feasible. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF